Healthcare · NIFTY 500

Ajanta Pharma Limited

NSEAJANTPHARM BSE532331 ISININE031B01049 SeriesEQ Listed on NSE · BSE · MSEI

₹3,324.00 +4.40 (+0.13%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+26.40% in a year

Today

Open: ₹3,310.00
Prev close: ₹3,319.60
Day high: ₹3,362.00
Day low: ₹3,285.00
Volume: 1.10 L
Value traded: ₹36.82 Cr
Upper circuit: ₹3,983.50
Lower circuit: ₹2,655.70
52W high: ₹3,796.00
52W low: ₹2,445.80
1 month: -3.95%
6 months: +7.70%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹41,666 Cr

P/E (TTM)32.91

P/B8.58

Book value / share₹387.58

EPS (TTM)₹101.00

ROE25.9%

Dividend yield0.96%

Dividend (12m)₹32.00 / share

Net margin (TTM)20.2%

Operating margin30.5%

Debt / equity0.02

Current ratio2.85

EV / EBITDA24.71

Sales growth (YoY qtr)+32.53%

Profit growth (YoY qtr)+49.18%

Sales CAGR 3Y+13.37%

Profit CAGR 3Y—

Shares12.54 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

1,1050.0

Dec 23

1,054196

Mar 24

1,145238

Jun 24

1,187216

Sep 24

1,146233

Dec 24

1,170225

Mar 25

1,303255

Jun 25

1,354260

Sep 25

1,375274

Dec 25

1,422267

Mar 26

1,626330

Jun 26

1,794388

Sep 26

Revenue · QoQ (vs last quarter)

—-4.6%+8.6%+3.6%-3.4%+2.1%+11%+3.9%+1.6%+3.4%+14%+10%

Revenue · YoY (vs a year ago)

————+3.7%+11%+14%+14%+20%+21%+25%+33%

Net profit · QoQ (vs last quarter)

——+21%-9.2%+7.6%-3.3%+13%+1.9%+5.2%-2.6%+24%+18%

Net profit · YoY (vs a year ago)

—————+15%+7.1%+20%+18%+18%+29%+49%

RevenueNet profitLine = trend

16.67

Dec 23

16.09

Mar 24

19.53

Jun 24

17.26

Sep 24

18.59

Dec 24

18.00

Mar 25

20.43

Jun 25

20.82

Sep 25

21.91

Dec 25

21.34

Mar 26

26.72

Jun 26

31.03

Sep 26

EPS (₹) · YoY (vs a year ago)

————+12%+12%+4.6%+21%+18%+19%+31%+49%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	1,105	1,054	1,145	1,187	1,146	1,170	1,303	1,354	1,375	1,422	1,626	1,794
Other income	13.6	35.5	26.5	19.5	30.4	18.1	26.3	59.3	25.0	61.4	70.9	37.4
Total income	1,119	1,090	1,171	1,206	1,177	1,189	1,329	1,413	1,400	1,483	1,697	1,832
Raw material	239	259	238	207	210	191	207	218	235	257	297	349
Purchases	39.3	40.4	45.3	45.8	78.6	80.2	51.6	53.3	53.6	71.4	66.9	80.9
Employee cost	231	234	284	261	265	280	303	317	331	341	381	384
Other expenses	266	278	263	353	302	310	373	392	376	443	493	478
Total expenses	828	812	849	916	869	919	998	1,072	1,041	1,136	1,250	1,296
Operating profit	314	278	330	311	321	297	351	328	382	333	424	548
OPM %	28.4%	26.4%	28.9%	26.2%	28.0%	25.4%	27.0%	24.2%	27.8%	23.5%	26.1%	30.5%
Finance cost	2.5	1.5	0.7	6.0	7.9	6.1	5.3	3.4	5.1	2.4	3.2	2.2
Depreciation	34.3	34.3	34.0	34.4	36.0	39.8	41.3	43.0	43.5	45.4	44.5	47.6
Profit before tax	291	278	322	290	307	269	331	341	359	347	447	535
Tax	80.9	75.3	76.4	73.8	74.5	44.2	75.8	80.6	84.8	80.4	113	147
Net profit	210	203	246	216	233	225	255	260	274	267	334	388
Profit to shareholders	0.0	196	238	216	233	225	255	260	274	267	330	—
EPS (₹)	16.67	16.09	19.53	17.26	18.59	18.00	20.43	20.82	21.91	21.34	26.72	31.03

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

2,055566384

FY19

2,588679468

FY20

2,890999654

FY21

3,3419290.0

FY22

3,7437830.0

FY23

4,2091,172817

FY24

4,6481,260920

FY25

5,4531,3951,056

FY26

Revenue · YoY (vs a year ago)

—+26%+12%+16%+12%+12%+10%+17%

Net profit · YoY (vs a year ago)

—+22%+40%-100%——+13%+15%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	2,055	2,588	2,890	3,341	3,743	4,209	4,648	5,453
Other income	21.1	92.2	26.0	116	98.6	84.6	94.5	172
Total expenses	1,562	2,012	2,015	2,547	3,096	3,179	3,553	4,247
Employee cost	431	486	548	646	785	900	1,090	1,291
Operating profit	566	679	999	929	783	1,172	1,260	1,395
OPM %	27.6%	26.3%	34.6%	27.8%	20.9%	27.8%	27.1%	25.6%
Finance cost	1.2	11.9	8.3	10.2	5.8	7.2	20.7	16.1
Depreciation	72.1	95.7	116	125	131	135	144	173
Profit before tax	514	664	900	909	745	1,114	1,189	1,378
Tax	127	196	246	197	157	298	269	322
Tax rate %	24.8%	29.6%	27.4%	21.6%	21.1%	26.7%	22.6%	23.3%
Net profit	387	468	654	713	588	816	920	1,056
Profit to shareholders	384	—	—	0.0	0.0	817	920	1,056
Net margin %	18.7%	18.1%	22.6%	0.0%	0.0%	19.4%	19.8%	19.4%
EPS (₹)	43.96	53.60	75.09	82.45	45.89	64.77	73.53	84.51

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

3,3881.4330

Mar 23

3,5671.5129

Mar 24

3,7902.6175

Mar 25

4,527212103

Mar 26

4,85810490.2

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+5.3%+6.2%+19%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	3,388	3,567	3,790	4,527	4,858
Long-term borrowings	1.3	0.0	0.0	0.0	0.0
Short-term borrowings	0.2	1.5	2.6	212	104
Total borrowings	1.4	1.5	2.6	212	104
Current liabilities	1,139	895	996	1,416	1,343
Fixed assets (PPE)	1,408	1,384	1,625	1,726	1,783
Inventories	816	828	904	939	967
Trade receivables	1,057	1,247	1,183	1,854	1,864
Cash & equivalents	330	129	175	103	90.2
Current assets	2,825	2,722	2,830	3,735	3,823
Total assets	4,679	4,638	5,015	6,155	6,425
Debt / equity	0.00	0.00	0.00	0.05	0.02

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

562-74.1-460

FY22

792-560-108

FY23

78565.4-1,051

FY24

1,157-377-733

FY25

529-429-168

FY26

Operations · YoY (vs a year ago)

—+41%-0.8%+47%-54%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	562	792	785	1,157	529
Cash from investing	-74.1	-560	65.4	-377	-429
Cash from financing	-460	-108	-1,051	-733	-168
Spent on fixed assets	-149	-174	-152	-318	-365
Free cash flow	413	617	633	839	164
Net cash flow	27.9	124	-201	47.3	-67.7

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

66.2%Dec 23

66.2%Mar 24

66.3%Jun 24

66.3%Sep 24

66.3%Dec 24

66.3%Mar 25

66.3%Jun 25

66.3%Sep 25

66.3%Dec 25

66.3%Mar 26

63.5%Jun 26

63.5%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

63.5%promoter

Promoter & group: 63.47%
Public (FIIs, mutual funds, retail…): 36.53%
Promoter change, last quarter: -0.01 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Interim Dividend - Rs 32 Per ShareEx 05-Aug-2026
Interim Dividend - Rs 28 Per ShareEx 10-Nov-2025
Interim Dividend - Rs 28 Per ShareEx 06-Nov-2024
Buy BackEx 30-May-2024
Interim Dividend - Rs 26 Per ShareEx 08-Feb-2024
Interim Dividend - Rs 10 Per Share/Special Dividend - Rs 15 Per ShareEx 04-Aug-2023
Buy BackEx 24-Mar-2023
Interim Dividend - Rs 7 Per ShareEx 11-Nov-2022

Board meetings

AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financ…30-Oct-2026
the financial results for the period ended September 30, 202630-Oct-2026
the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Dividend.30-Jul-2026
the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Dividend.30-Jul-2026
dividend30-Jul-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates4 Nov
Copy of Newspaper Publication2 Nov
Analysts/Institutional Investor Meet/Con. Call Updates30 Oct
Outcome of Board Meeting30 Oct
Analysts/Institutional Investor Meet/Con. Call Updates15 Oct
Certificate under SEBI (Depositories and Participants) Regulations, 20187 Oct
General Updates30 Sep

Latest news

Ajanta Pharma Shares Rise 2.17%Moneycontrol.com · 14 Aug, 12:30 pm Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal StreetLivemint · 20 Jul, 12:30 pm Stock to buy today: Ajanta Pharma (₹3,073) – BUYBusinessLine · 11 Jun, 12:30 pm Ajanta Pharma shares fall 2.06%, trading at Rs 3,365.60TradingView · 31 Jul, 12:30 pm Ajanta Pharma (NSEI:AJANTPHARM) Stock Forecast & Analyst PredictionsSimply Wall St · 2 Nov, 1:30 pm Ajanta Pharma gets USFDA inspection report for Paithan manufacturing facility; shares trade flatUpstox · 2 Jul, 12:30 pm Ajanta Pharma hits over 5-month high after partnering with BioconBusiness Standard · 24 Dec, 1:30 pm Ajanta Pharma Q3FY26 Profit Rises 17.6% to ₹274 Crore, Revenue Up 20%India Infoline · 30 Jan, 1:30 pm

About

About Ajanta Pharma Limited

Ajanta Pharma Limited (APL) is an Indian multinational pharmaceutical company. The company operates in India, the United States, and over 30 countries across Africa, Southeast Asia, West Asia, and the CIS. It was established in 1973..

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Ajanta Pharma Limited
NSE symbol: AJANTPHARM
BSE scrip code: 532331
ISIN: INE031B01049
Listed on: NSE, BSE, MSEI
Series: EQ (normal equity)
Listed on NSE since: 29 May 2000
Face value: ₹2 per share
Market lot: 1 share
Shares issued: 12.54 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Yogesh Agrawal
Chair: Mannalal Agrawal
Headquarters: Mumbai, Maharashtra, India
Registered address: Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai 400 093, Maharashtra, India.
Founded: 1973
Employees: 13,206
Financial year: April to March
Results basis: Consolidated
Website: ajantapharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Ajanta Pharma Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers